Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery

Haidar, Ziyad S.; Hamdy, Reggie C.; Tabrizian, Maryam

doi:10.1007/s10529-009-0099-x

Cited by 216 publications

(226 citation statements)

References 49 publications

Supporting

Mentioning

220

Contrasting

Order By: Relevance

“…[16][17][18] Some documents have shown that BMP4 exacerbates exaggeratin cardiac I/R injury. 19 In addition, BMP4 is a proinflammatory gene that induces endothelium dysfunction, mediating abnormal expression of endothelial nitric oxide synthase (eNOS) and leads to impairment of vascular relaxation, 20 and that activates NADPH oxidase to induce ROS production and then improves the expression of cyclooxygenase-2 (COX-2) through p38 mitogen-activated protein kinase (p38MAPK).…”

mentioning

confidence: 99%

Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats

Tong

Dong

Chai

et al. 2017

IJN

View full text Add to dashboard Cite

mentioning

confidence: 99%

Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats

Tong

Dong

Chai

et al. 2017

IJN

View full text Add to dashboard Cite

“…165 Moreover, different anatomical sites require therapeutic doses depending on degree of vascularization, defect size, and number of resident cells. 325 Therefore, appropriate carrier systems are critical for the delivery, retention, and release of GFs at the implanted site to achieve the desired effect. 68,326 Despite the differences in the use of scaffold carriers, GFs dosages and combinations, animal models, and consequently the tissue regeneration outcomes, the potential of GF therapy are undeniable.…”

Section: From Single To Multiple Bioactive Factor Delivery For Skeletmentioning

confidence: 99%

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

Santo

Gomes²,

Mano³

et al. 2013

Tissue Engineering Part B: Reviews

102

View full text Add to dashboard Cite

The development of controlled release systems for the regeneration of bone, cartilage, and osteochondral interface is one of the hot topics in the field of tissue engineering and regenerative medicine. However, the majority of the developed systems consider only the release of a single growth factor, which is a limiting step for the success of the therapy. More recent studies have been focused on the design and tailoring of appropriate combinations of bioactive factors to match the desired goals regarding tissue regeneration. In fact, considering the complexity of extracellular matrix and the diversity of growth factors and cytokines involved in each biological response, it is expected that an appropriate combination of bioactive factors could lead to more successful outcomes in tissue regeneration. In this review, the evolution on the development of dual and multiple bioactive factor release systems for bone, cartilage, and osteochondral interface is overviewed, specifically the relevance of parameters such as dosage and spatiotemporal distribution of bioactive factors. A comprehensive collection of studies focused on the delivery of bioactive factors is also presented while highlighting the increasing impact of platelet-rich plasma as an autologous source of multiple growth factors.

show abstract

“…The efficacy of rhBMPs will depend on the carrier system that is used to ensure an effective delivery of adequate protein concentrations to the desired site [11,20]. The PTD delivery system has various advantages, including high efficiency in vivo, low toxicity, and controllability of administration, compared with other methods such as viral vector-mediated gene delivery and liposomal delivery [23].…”

Section: Determination Of Rhbmp2/7-ptd Expression Levelsmentioning

confidence: 99%

“…However, the precise cellular and molecular mechanisms of BMPs are not fully understood and require further investigation [8,11].…”

Section: Determination Of Rhbmp2/7-ptd Expression Levelsmentioning

confidence: 99%

Establishment of a Stable Cell Line Expressing Human BMP2/7-PTD for Efficient Osteogenic Induction

Park¹,

Kang²,

Goo³

et al. 2012

Journal of Life Science

View full text Add to dashboard Cite

Heterodimeric recombinant human bone morphogenetic proteins (rhBMPs) are powerful tools for bone tissue engineering. However, BMPs have several important limitations in their application to bone regeneration. BMPs have a short half-life and must be used in high concentrations, which may be cost-inefficient. To overcome these problems, we established a stable cell line that expressed the fusion protein comprised of recombinant human BMP2/7 heterodimer protein and PTD (rhBMP2/7-PTD). This stable cell line enabled high process yields by continuously expressing rhBMP2/7-PTD products at high levels throughout cultivation. This synthesized BMP7 was fused to a BMP2 protein with four glycine residues (to allow free bond rotation of the domains) and PTD. To demonstrate that the rhBMP2/7-PTD protein that was secreted from an rhBMP2/7-PTD-expressing stable cell line exhibited biological activity consistent with its role as an osteogenic differentiation induction growth factor, we evaluated BMP-induced ALP activity. Our results suggest that this cell line may be a powerful and efficient tool for applications such as bone tissue regeneration.

show abstract

Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery

Cited by 216 publications

References 49 publications

Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats

Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

Establishment of a Stable Cell Line Expressing Human BMP2/7-PTD for Efficient Osteogenic Induction

Contact Info

Product

Resources

About